SAB Biotherapeutics Q2 FY26 net loss widens to $22.5 million; R&D expenses more than doubled to $16.2 millionPUBT·Aug 6 at 06:37 AMSABS-3.56%
SAB Biotherapeutics (NASDAQ:SABS) Trading Up 0.6% - Still a Buy?Market Beat·Jul 16 at 01:00 AMSABS-3.56%STT-0.02%
Breakthrough T1D awards grant to support UF-led PRISE-hATG study of SAB Bio’s SAB-142 in stage 3 type 1 diabetesPUBT·Jul 7 at 07:06 AMSABS-3.56%
SAB Biotherapeutics shareholders elect four Class II directors at annual meetingPUBT·Jun 18 at 03:36 PMSABS-3.56%
12 Health Care Stocks Moving In Monday's Intraday Sessionbenzinga_article·Jun 15 at 12:05 PMCYPH-9.52%GNPX+1.66%
Paychex To Rally More Than 39%? Here Are 10 Top Analyst Forecasts For Mondaybenzinga_article·Jun 15 at 08:55 AMDDOG-2.45%PDM-1.75%
This QuickLogic Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesdaybenzinga_article·May 20 at 07:53 AMQUIK-4.51%SABS-3.56%
Chardan Capital Keeps Their Buy Rating on SAB Biotherapeutics (SABS)Tip Ranks·May 12 at 10:55 PMSABS-3.56%
